Abbvie Inc

Change company Symbol lookup

Select an option...

ABBV Abbvie Inc

PARA Paramount Global

TFINP Triumph Financial Inc

HWKN Hawkins Inc

COUP Coupa Software Inc

ACAZF Acadian Timber Corp

BSX Boston Scientific Corp

ACDVF Air Canada

DCFCW Tritium DCFC Equity Warrant Exp 13th Jan 2027 *W EXP 01/13/2027

CBWTF Auxly Cannabis Group Inc

Go

Allergan Aesthetics, an AbbVie company (NYSE: ABBV), today unveiled at the 24th International Master Course on Aging Science (IMCAS) World Congress its immersive experience 'Discover your 360°'. This is a customer centric approach, which supports...(PR Newswire)

With JUVÉDERM(R) VOLUX™ XC, You Can Receive Non-Surgical Jawline Augmentation in Your Aesthetic Provider's Office Today, Allergan Aesthetics, an AbbVie company (NYSE:ABBV), announced the highly anticipated national launch of JUVÉDERM(R)VOLUX™ XC...(PR Newswire)

The Results Are Clear - A Scientifically Proven Path to Targeting the Appearance of Hyperpigmentation and Improving Skin Tone and Texture Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announces the launch of the long-awaited...(PR Newswire)

Collaboration leverages Anima's mRNA Lightning technology platform and AbbVie's extensive expertise in Oncology and Immunology- Anima will receive an upfront payment of $42 million with potential for further milestones and royalties (PR Newswire)

Multi-year collaboration to identify up to 10 novel target-antibody pairs leveraging Immunome's Discovery Engine- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development...(PR Newswire)

--- Immunome to receive $30M upfront payment with potential for further platform access and option payments as well as development, commercial, and sales-based milestones, and tiered royalties AbbVie (NYSE: ABBV) and Immunome, Inc. (Nasdaq: IMNM), a...(BusinessWire)

AbbVie (NYSE: ABBV) will announce its fourth-quarter 2022 financial results on Thursday, February 9, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie's...(PR Newswire)

AbbVie (NYSE: ABBV) will participate in the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023. Richard A. Gonzalez, chairman and chief executive officer, will present at 5:00 p.m. CT. (PR Newswire)

Approval marks fourth indication for VRAYLAR, backed by proven efficacy and well-established tolerability as an adjunctive treatment for major depressive disorder (MDD) with an antidepressant therapy (ADT), showing improvement in symptoms when...(PR Newswire)

-- If approved, linaclotide would be the first prescription therapy for functional constipation in children and adolescents 6 to 17 years of age 1 -- Submission is based on positive Phase 3 study data demonstrating linaclotide (72mcg) resulted in...(PR Newswire)

AbCellera (Nasdaq: ABCL) announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. (NYSE: ABBV). The partnership will leverage AbCellera's antibody discovery and development engine to deliver...(BusinessWire)

-- AbbVie Ranked #1 in Biotech Sector on the 2022 S&P Corporate Sustainability Assessment AbbVie (NYSE: ABBV) today announced that for the tenth consecutive year, it has been named to the Dow Jones Sustainability World Index (DJSI World) and Dow...(PR Newswire)

-- Four oral presentations presented at ASH highlight data evaluating investigational epcoritamab for the treatment of relapsed/refractory (R/R) follicular lymphoma, previously untreated follicular lymphoma, R/R diffuse large B-cell lymphoma and...(PR Newswire)

-- Exploratory analysis from Cohort 3 of the Phase 2 REFINE study presented in an oral session at ASH AbbVie (NYSE: ABBV) today announced new data from Cohort 3 of its Phase 2 REFINE study of investigational navitoclax in combination with...(PR Newswire)

-- Collaboration leverages HotSpot's Smart Allostery™drug discovery platform for the development of the first and only small molecule IRF5 (interferon regulatory factor 5) inhibitor for the potential treatment of autoimmune diseases (PR Newswire)

Fifteen abstracts underscore AbbVie's commitment to people living with migraine -- AbbVie to present late-breaking data from the Chronic Migraine Epidemiology and Outcomes - International (CaMEO-I) study on neck pain with headache in people with and...(PR Newswire)

FinancialNewsMedia.com News Commentary - Pancreatic cancer accounts for over 3% of all types of cancers in US. A lethal type of cancer, pancreatic cancer starts in the pancreas of the human body when abnormal cells in the pancreas grow and divide...(PR Newswire)

AbbVie (NYSE: ABBV) will participate in the 5th Annual Evercore ISI Virtual HealthCONx Conference on Tuesday, November 29, 2022. Rob Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, commercial operations, Scott...(PR Newswire)

Third approved indication for SKYRIZI(R)(risankizumab) and the first specific IL-23 inhibitor for the treatment of Crohn's disease in the European Union (EU) - A significantly higher proportion of patients on SKYRIZI achieved clinical remission...(PR Newswire)